

Soo-Mee Bang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2844304/publications.pdf>

Version: 2024-02-01

168
papers

2,003
citations

279798

23
h-index

330143

37
g-index

172
all docs

172
docs citations

172
times ranked

3543
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 42-52.	5.3	230
2	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1086-1097.	3.0	59
3	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	2.5	57
4	Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey. <i>Journal of Korean Medical Science</i> , 2014, 29, 224.	2.5	56
5	Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines. <i>Journal of Korean Medical Science</i> , 2014, 29, 164.	2.5	55
6	Incidence of venous thromboembolism in Korea from 2009 to 2013. <i>PLoS ONE</i> , 2018, 13, e0191897.	2.5	55
7	Metabolic Syndrome Is Associated With Venous Thromboembolism in the Korean Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 311-315.	2.4	54
8	Venous thromboembolism in patients with pancreatic adenocarcinoma: Lower incidence in Asian ethnicity. <i>Thrombosis Research</i> , 2008, 122, 485-490.	1.7	52
9	Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. <i>Thrombosis Research</i> , 2017, 155, 86-91.	1.7	46
10	Changes in quality of life during palliative chemotherapy for solid cancer. <i>Supportive Care in Cancer</i> , 2005, 13, 515-521.	2.2	41
11	Anemia and activities of daily living in the Korean urban elderly population: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA). <i>Annals of Hematology</i> , 2013, 92, 59-65.	1.8	36
12	Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1084-1094..	3.4	33
13	Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis. <i>European Journal of Cancer</i> , 2014, 50, 2810-2821.	2.8	33
14	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 83, 309-313.	1.6	32
15	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. <i>Annals of Hematology</i> , 2010, 89, 201-206.	1.8	30
16	Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. <i>International Journal of Hematology</i> , 2017, 106, 229-239.	1.6	30
17	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	1.8	30
18	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. <i>Cancer Research and Treatment</i> , 2015, 47, 501-508.	3.0	29

#	ARTICLE	IF	CITATIONS
19	Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 168, 124-132.	1.0	28
20	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28
21	Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study. <i>PLoS ONE</i> , 2017, 12, e0178214.	2.5	28
22	Korean Guidelines for the Prevention of Venous Thromboembolism. <i>Journal of Korean Medical Science</i> , 2010, 25, 1553.	2.5	26
23	Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. <i>Blood Advances</i> , 2019, 3, 3700-3708.	5.2	26
24	Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. <i>International Journal of Hematology</i> , 2009, 90, 1-5.	1.6	25
25	Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. <i>Thrombosis Research</i> , 2015, 135, 846-851.	1.7	24
26	Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. <i>Journal of Korean Medical Science</i> , 2016, 31, 1579.	2.5	24
27	Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome.. <i>Blood</i> , 2012, 120, 2843-2843.	1.4	23
28	Guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 771-788.	1.7	22
29	Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. <i>PLoS ONE</i> , 2018, 13, e0198544.	2.5	21
30	Management of immune thrombocytopenia: Korean experts recommendation in 2017. <i>Blood Research</i> , 2017, 52, 254.	1.3	20
31	The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants. <i>Thrombosis Research</i> , 2020, 195, 243-249.	1.7	20
32	PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. <i>Scientific Reports</i> , 2020, 10, 12308.	3.3	20
33	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259.	1.3	18
34	The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
35	Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. <i>BMC Cancer</i> , 2019, 19, 358.	2.6	18
36	Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. <i>Annals of Hematology</i> , 2019, 98, 151-158.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. <i>American Journal of Hematology</i> , 2011, 86, 752-755.	4.1	17
38	Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. <i>Annals of Hematology</i> , 2016, 95, 1777-1786.	1.8	17
39	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	4.1	17
40	Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. <i>Acta Haematologica</i> , 2019, 141, 176-186.	1.4	16
41	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
42	Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 978-989.	3.0	16
43	High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1599-1604.	1.3	15
44	Hereditary Hemolytic Anemia in Korea: a Retrospective Study from 1997 to 2006. <i>The Korean Journal of Hematology</i> , 2007, 42, 197.	0.7	15
45	Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia. <i>Journal of Korean Medical Science</i> , 2008, 23, 833.	2.5	15
46	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 201, 63-72.	1.7	14
47	Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2010, 44, 39-44.	1.0	13
48	Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 117-121.	1.0	13
49	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. <i>Haematologica</i> , 2017, 102, e187-e190.	3.5	13
50	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 45-62.	1.7	13
51	Differences in characteristics between first and breakthrough neutropenic fever after chemotherapy in patients with hematologic disease. <i>International Journal of Infectious Diseases</i> , 2016, 44, 4-7.	3.3	12
52	Dapsone therapy for refractory immune thrombocytopenia patients: a case series. <i>Blood Research</i> , 2017, 52, 95.	1.3	12
53	Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. <i>Thrombosis Research</i> , 2019, 183, 131-135.	1.7	12
54	Clinical history of cancer-associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 983-991.	3.8	12

#	ARTICLE	IF	CITATIONS
55	Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants. <i>Journal of Korean Medical Science</i> , 2019, 34, e52.	2.5	12
56	Epidemiological Change of Multiple Myeloma in Korea. <i>The Korean Journal of Hematology</i> , 2006, 41, 225.	0.7	11
57	Updated recommendations for the treatment of venous thromboembolism. <i>Blood Research</i> , 2021, 56, 6-16.	1.3	11
58	Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1125-1135.	1.7	11
59	Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. <i>Annals of Hematology</i> , 2010, 89, 15-23.	1.8	10
60	A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. <i>PLoS ONE</i> , 2018, 13, e0205853.	2.5	10
61	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	1.6	9
62	High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study. <i>Journal of Korean Medical Science</i> , 2003, 18, 673.	2.5	8
63	Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies. <i>Infection and Chemotherapy</i> , 2017, 49, 135.	2.3	8
64	Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 2507-2515.	2.2	8
65	Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report. <i>The Korean Journal of Hepatology</i> , 2011, 17, 323.	1.5	8
66	Cost Analysis of Iron-Related Complications in a Single Institute. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 33.	1.7	8
67	Human Herpesvirus 8-Related Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. <i>Cancer Research and Treatment</i> , 2017, 49, 274-278.	3.0	8
68	Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. <i>Medical Oncology</i> , 2008, 25, 81-87.	2.5	7
69	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450.	2.5	7
70	Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer. <i>PLoS ONE</i> , 2015, 10, e0120324.	2.5	7
71	Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 503-510.e3.	0.4	7
72	Serum Free Light Chain Difference and β_2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 408-414.	0.4	7

#	ARTICLE	IF	CITATIONS
73	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. <i>Cells</i> , 2019, 8, 1538.	4.1	7
74	<i>Pneumocystis jirovecii</i> pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP. <i>Mycoses</i> , 2021, 64, 60-65.	4.0	7
75	Prominent seasonal variation in pulmonary embolism than deep vein thrombosis incidence: a Korean venous thrombosis epidemiology study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 682-691.	1.7	7
76	Incidence of Venous Thromboembolism: The 3 rd Korean Nationwide Study. <i>Journal of Korean Medical Science</i> , 2022, 37, e130.	2.5	7
77	Sequential eradication of <i>Helicobacter pylori</i> as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study. <i>Annals of Hematology</i> , 2022, 101, 1435-1445.	1.8	7
78	Acute Exacerbation of Chronic Hepatitis B During Thalidomide Therapy for Multiple Myeloma: A Case Report. <i>Korean Journal of Internal Medicine</i> , 2004, 19, 196-198.	1.7	6
79	Extramedullary peritoneal hematopoiesis combined with tuberculosis in a patient with primary myelofibrosis. <i>Medical Oncology</i> , 2009, 26, 238-241.	2.5	6
80	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193.	1.3	6
81	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2016, 11, e0166245.	2.5	6
82	Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms. <i>Scientific Reports</i> , 2021, 11, 17819.	3.3	6
83	Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort. <i>Cancer Research and Treatment</i> , 2015, 47, 215-220.	3.0	6
84	Diagnostic and therapeutic guideline for myeloproliferative neoplasm. <i>Journal of the Korean Medical Association</i> , 2011, 54, 112.	0.3	5
85	Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. <i>Blood Research</i> , 2014, 49, 77.	1.3	5
86	Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 115-119.	2.0	5
87	Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP). <i>Journal of Korean Medical Science</i> , 2018, 33, e142.	2.5	5
88	Efficacy of parenteral glutamine supplementation in adult hematopoietic stem cell transplantation patients. <i>Blood Research</i> , 2019, 54, 23-30.	1.3	5
89	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
90	Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2995-3005.	2.5	5

#	ARTICLE	IF	CITATIONS
91	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	4
92	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7.	1.3	4
93	Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study. <i>In Vivo</i> , 2019, 33, 2273-2280.	1.3	4
94	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center. <i>Annals of Palliative Medicine</i> , 2020, 9, 216-223.	1.2	4
95	Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2021, 100, 2567-2574.	1.8	4
96	Platelet count as an important prognostic factor for vaccine-induced immune thrombotic thrombocytopenia. <i>Blood Research</i> , 2021, 56, 129-133.	1.3	4
97	Clinical Features of Waldenstrom Macroglobulinemia in Korea. <i>Korean Journal of Internal Medicine</i> , 2004, 19, 137-140.	1.7	4
98	Diagnostic Usefulness of the Janus Kinase 2 Mutation in non-BCR/ABL Myeloproliferative Disorders. <i>Korean Journal of Internal Medicine</i> , 2006, 21, 219.	1.7	4
99	Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation. <i>Blood Research</i> , 2020, 55, 151-158.	1.3	4
100	Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 23803.	3.3	4
101	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0261671.	2.5	4
102	Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. <i>Thrombosis and Haemostasis</i> , 2009, 101, 547-51.	3.4	4
103	Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. <i>Anticancer Research</i> , 2015, 35, 5631-8.	1.1	4
104	Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population. <i>Annals of Hematology</i> , 2019, 98, 2357-2366.	1.8	3
105	Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards. <i>BMC Palliative Care</i> , 2019, 18, 93.	1.8	3
106	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
107	Vaccine-Induced Immune Thrombotic Thrombocytopenia: First Case Report in South Korea. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
109	Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. <i>Oncotarget</i> , 2017, 8, 79414-79424.	1.8	3
110	R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. <i>Blood Research</i> , 2021, 56, 285-292.	1.3	3
111	Recurrence of Cancer-associated Venous Thromboembolism between 2009 and 2013: A Nationwide Korean Study. <i>Clinical & Experimental Thrombosis and Hemostasis</i> , 2021, 7, 14-19.	0.2	3
112	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants. <i>Scientific Reports</i> , 2021, 11, 22403.	3.3	3
113	Primary Mediastinal Synovial Sarcoma. <i>Journal of Lung Cancer</i> , 2008, 7, 29.	0.2	2
114	The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation. <i>Anticancer Research</i> , 2020, 40, 357-366.	1.1	2
115	Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome. <i>Blood Research</i> , 2020, 55, 27-34.	1.3	2
116	Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097957.	1.7	2
117	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	2.1	2
118	A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma. <i>Korean Journal of Internal Medicine</i> , 2011, 26, 403.	1.7	2
119	Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alyone. <i>Blood</i> , 2021, 138, 1661-1661.	1.4	2
120	How myeloproliferative neoplasms patientsâ€™ experience and expectations differ from physiciansâ€™: the international MPN Landmark survey. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 444-454.	1.7	2
121	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2022, 101, 1217-1226.	1.8	2
122	Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Research</i> , 2022, 57, S37-S43.	1.3	2
123	Targeting the protein kinases for anti-cancer therapy. <i>The Korean Journal of Hematology</i> , 2012, 47, 157.	0.7	1
124	Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea. <i>Medicine (United States)</i> , 2019, 98, e16318.	1.0	1
125	Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110011.	2.5	1
126	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 1792-1792.	1.4	1

#	ARTICLE	IF	CITATIONS
127	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. Blood, 2009, 114, 4902-4902.	1.4	1
128	Factors Affecting Clinical Outcomes after CLAG/CLAG-M Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2014, 124, 5289-5289.	1.4	1
129	A Multicenter, Phase III Clinical Trial of Leucogreen®(G-CSF) for Chemotherapy-Induced Neutropenia in Solid Tumors. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2003, 11, 38.	0.1	1
130	Prognostic Significance of ABCB1 (MDR1) Gene Polymorphisms in De Novo Acute Myeloid Leukemia with t(8;21) or inv(16).. Blood, 2007, 110, 4271-4271.	1.4	1
131	Prognostic Significance of FLT3/ITD Mutation in AML1/ETO-Associated Acute Myeloid Leukemia.. Blood, 2007, 110, 3493-3493.	1.4	1
132	Diagnosis and Treatment of Venous Thromboembolism in Cancer Patients. Korean Journal of Medicine, 2013, 85, 481.	0.3	1
133	Epidemiology and Management of Immune Thrombocytopenia: A Nationwide Population-Based Study in Korea. Blood, 2016, 128, 4934-4934.	1.4	1
134	Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone. Blood, 2021, 138, 1648-1648.	1.4	1
135	Donor Lymphocyte Infusions for Patients with Relapsed Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: a 10-year Experience of Seoul National University Hospital. The Korean Journal of Hematology, 2007, 42, 233.	0.7	0
136	Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. Journal of Clinical Laboratory Analysis, 2016, 30, 1061-1070.	2.1	0
137	Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. Blood Research, 2019, 54, 290-295.	1.3	0
138	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. Current Problems in Cancer, 2021, 46, 100786.	2.0	0
139	Primary Gastric T-Cell Lymphoma: Clinicopathologic Features and Treatment Outcome.. Blood, 2005, 106, 3355-3355.	1.4	0
140	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. Blood, 2005, 106, 1491-1491.	1.4	0
141	Diagnostic Usefulness of JAK2 Mutation in Manitest or Latent Polycythemia Vera and Secondary Polycythemia.. Blood, 2006, 108, 4901-4901.	1.4	0
142	Pharmacokinetics and Tolerability of Intravenous Busulfan in Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 5249-5249.	1.4	0
143	Evolution of FLT3 Internal Tandem Duplication at the Diagnosis, Relapse, Remission or Induction Failure during the Treatment in Acute Myeloblastic Leukemia.. Blood, 2006, 108, 4485-4485.	1.4	0
144	JAK2 V617F Mutation in Essential Thrombocythemia.. Blood, 2006, 108, 4925-4925.	1.4	0

#	ARTICLE	IF	CITATIONS
145	A Report of AIDS-Related Lymphoma (ARL) in Korea.. Blood, 2006, 108, 4687-4687.	1.4	0
146	The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.. Blood, 2007, 110, 4615-4615.	1.4	0
147	Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?. Blood, 2008, 112, 5146-5146.	1.4	0
148	Changes of Platelet and Endothelial Microparticles in Patients with Venous Thromboembolism. Blood, 2008, 112, 3829-3829.	1.4	0
149	Patients with Hematologic Malignancies May Be at Higher Risk of Hepatitis B Reactivation in Spite of Lamivudine Prophylaxis.. Blood, 2009, 114, 1389-1389.	1.4	0
150	Incidence and Biologic Features of 5q Deletion and 5q- Syndrome in Myelodysplastic Syndrome in Korea; According to Reclassification of Myelodysplastic Syndrome by WHO 2008.. Blood, 2009, 114, 2778-2778.	1.4	0
151	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. Blood, 2009, 114, 4881-4881.	1.4	0
152	Clinical Efficacy and Tolerability of Granulocyte Transfusions for the Treatment of Febrile Neutropenia in the Patients with Hematologic Malignancies.. Blood, 2009, 114, 3146-3146.	1.4	0
153	Prevalence and Risk Factors of Iron Deficiency Anemia in Korea: The Fifth Korean Health and Nutrition Examination Survey (KNHANES V-1). Blood, 2012, 120, 5170-5170.	1.4	0
154	Five-Years' Follow-up Study for Frequency of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Korean Elderly Urban Cohort. Blood, 2012, 120, 5007-5007.	1.4	0
155	Five yearsâ€™ Follow-Up Study For Frequency Of Monoclonal Gammopathy Of Undetermined Significance (MGUS) In a Korean Elderly Urban Cohort. Blood, 2013, 122, 5332-5332.	1.4	0
156	Incidence Of VTE Following Genitourinary Surgery In Korea and Evidence-Based Korean Guidelines For Preventing VTE In Patients Undergoing Genitourinary Surgery. Blood, 2013, 122, 1138-1138.	1.4	0
157	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. Blood, 2014, 124, 592-592.	1.4	0
158	Similar Levels of Complement Activation in Both Patients with Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome: The Report from the Korean TTP Registry. Blood, 2014, 124, 4195-4195.	1.4	0
159	Venous Thromboembolism Following L-Asparaginase Treatment in Hematologic Malignancies in Korea. Blood, 2015, 126, 4679-4679.	1.4	0
160	Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials. Blood, 2016, 128, 1902-1902.	1.4	0
161	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. Blood, 2016, 128, 4222-4222.	1.4	0
162	Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP). Blood, 2016, 128, 4938-4938.	1.4	0

#	ARTICLE	IF	CITATIONS
163	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
164	Quality-of-Life and Health Behaviors in Survivors of Acute Leukemia Compared with the General Population: A Population-Based Matched Case-Control Study. <i>Blood</i> , 2016, 128, 5981-5981.	1.4	0
165	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. <i>Blood</i> , 2018, 132, 3876-3876.	1.4	0
166	JAK2 V617F-Positive Acute Myeloid Leukemia: Clinicopathological Features of Two Cases. <i>Laboratory Medicine Online</i> , 2022, 12, 53-57.	0.2	0
167	Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
168	Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study. <i>Thrombosis Research</i> , 2022, 213, 114-118.	1.7	0